Analyst Rating Update on Puma Biotechnology Inc (PBYI)

Puma Biotechnology Inc (NYSE:PBYI) : The consensus on Puma Biotechnology Inc (NYSE:PBYI) based on 6 analyst recommendation on the company stock is 2, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Puma Biotechnology Inc (NYSE:PBYI) : 3 Wall Street analysts covering Puma Biotechnology Inc (NYSE:PBYI) believe that the average level the stock could reach for the short term is $57. The maximum price target given is $75 and the minimum target for short term is around $36, hence the standard deviation is calculated at $19.67.

For the current week, the company shares have a recommendation consensus of Buy.

Puma Biotechnology Inc (NYSE:PBYI): stock turned positive on Tuesday. Though the stock opened at $28.5, the bulls momentum made the stock top out at $29.4 level for the day. The stock recorded a low of $28.08 and closed the trading day at $29.09, in the green by 4.64%. The total traded volume for the day was 695,877. The stock had closed at $27.8 in the previous days trading.

In an insider trading activity, The officer (SR VP, CLINICAL RESEARCH & DEV), of Puma Biotechnology, Inc., Bryce Richard Paul had unloaded 3,000 shares at $110.03 per share in a transaction on July 6, 2015. The total value of transaction was $330,090. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the acquisition, development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.